The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it's cheap Peter it's very cheap to make well I was going to say given that it's not an injectable monoclonal antibody this is cheap to make and um yeah it's actually very cheap to make I think this is public knowledge it will cost 36 dollars per year to make this drug at the time when you have lots of patients so what's called Peak sales
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.